A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: To study human teratogenic potential of oral oxytetracycline treatment during pregnancy. Materials and Methods: The pair analysis of cases with congenital abnormalities and matched healthy controls in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38,151 pregnant women who had babies without any defects in the study period (control group), 214 (0.6%) were treated with oral oxytetracycline. Of 22,865 pregnant women who had offspring with congenital abnormalities, 216 (0.9%) were treated with oxytetracycline (OR with 95%: 1.7, 1.4-2.0). Different approaches in the study showed a higher rate of medically documented oxytetracycline treatment in the second months of gestation in neural-tube defects (OR with 95%: 9.7, 2.0-47.1), cleft palate (17.2, 3.5-83.5) and multiple congenital abnormalities (12.9, 3.8-44.3) including mainly the combination of neural-tube defects and cardiovascular malformations. Conclusion: Treatment with oxytetracycline during the second months of pregnancy presents a teratogenic risk to the fetus. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume88
Issue number1
DOIs
Publication statusPublished - Jan 2000

Fingerprint

Oxytetracycline
Case-Control Studies
Pregnancy
Neural Tube Defects
Population
Pregnant Women
Multiple Abnormalities
Therapeutics
Cleft Palate
Fetus
Control Groups

Keywords

  • Case-control analysis
  • Multiple congenital abnormalities
  • Neural-tube defects
  • Oxytetracycline
  • Teratogenic potential

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

@article{e802bb2b5adb4be78dee75d98141df11,
title = "A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy",
abstract = "Objective: To study human teratogenic potential of oral oxytetracycline treatment during pregnancy. Materials and Methods: The pair analysis of cases with congenital abnormalities and matched healthy controls in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38,151 pregnant women who had babies without any defects in the study period (control group), 214 (0.6{\%}) were treated with oral oxytetracycline. Of 22,865 pregnant women who had offspring with congenital abnormalities, 216 (0.9{\%}) were treated with oxytetracycline (OR with 95{\%}: 1.7, 1.4-2.0). Different approaches in the study showed a higher rate of medically documented oxytetracycline treatment in the second months of gestation in neural-tube defects (OR with 95{\%}: 9.7, 2.0-47.1), cleft palate (17.2, 3.5-83.5) and multiple congenital abnormalities (12.9, 3.8-44.3) including mainly the combination of neural-tube defects and cardiovascular malformations. Conclusion: Treatment with oxytetracycline during the second months of pregnancy presents a teratogenic risk to the fetus. Copyright (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Case-control analysis, Multiple congenital abnormalities, Neural-tube defects, Oxytetracycline, Teratogenic potential",
author = "E. Czeizel and M. Rockenbauer",
year = "2000",
month = "1",
doi = "10.1016/S0301-2115(99)00112-8",
language = "English",
volume = "88",
pages = "27--33",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy

AU - Czeizel, E.

AU - Rockenbauer, M.

PY - 2000/1

Y1 - 2000/1

N2 - Objective: To study human teratogenic potential of oral oxytetracycline treatment during pregnancy. Materials and Methods: The pair analysis of cases with congenital abnormalities and matched healthy controls in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38,151 pregnant women who had babies without any defects in the study period (control group), 214 (0.6%) were treated with oral oxytetracycline. Of 22,865 pregnant women who had offspring with congenital abnormalities, 216 (0.9%) were treated with oxytetracycline (OR with 95%: 1.7, 1.4-2.0). Different approaches in the study showed a higher rate of medically documented oxytetracycline treatment in the second months of gestation in neural-tube defects (OR with 95%: 9.7, 2.0-47.1), cleft palate (17.2, 3.5-83.5) and multiple congenital abnormalities (12.9, 3.8-44.3) including mainly the combination of neural-tube defects and cardiovascular malformations. Conclusion: Treatment with oxytetracycline during the second months of pregnancy presents a teratogenic risk to the fetus. Copyright (C) 2000 Elsevier Science Ireland Ltd.

AB - Objective: To study human teratogenic potential of oral oxytetracycline treatment during pregnancy. Materials and Methods: The pair analysis of cases with congenital abnormalities and matched healthy controls in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38,151 pregnant women who had babies without any defects in the study period (control group), 214 (0.6%) were treated with oral oxytetracycline. Of 22,865 pregnant women who had offspring with congenital abnormalities, 216 (0.9%) were treated with oxytetracycline (OR with 95%: 1.7, 1.4-2.0). Different approaches in the study showed a higher rate of medically documented oxytetracycline treatment in the second months of gestation in neural-tube defects (OR with 95%: 9.7, 2.0-47.1), cleft palate (17.2, 3.5-83.5) and multiple congenital abnormalities (12.9, 3.8-44.3) including mainly the combination of neural-tube defects and cardiovascular malformations. Conclusion: Treatment with oxytetracycline during the second months of pregnancy presents a teratogenic risk to the fetus. Copyright (C) 2000 Elsevier Science Ireland Ltd.

KW - Case-control analysis

KW - Multiple congenital abnormalities

KW - Neural-tube defects

KW - Oxytetracycline

KW - Teratogenic potential

UR - http://www.scopus.com/inward/record.url?scp=0033989754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033989754&partnerID=8YFLogxK

U2 - 10.1016/S0301-2115(99)00112-8

DO - 10.1016/S0301-2115(99)00112-8

M3 - Article

C2 - 10659913

AN - SCOPUS:0033989754

VL - 88

SP - 27

EP - 33

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -